Definitive Contract 75A50118C00012
Award Date
9/21/18
Potential Completion Date
8/31/25
Potential Value
$229M
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Sharing
Place of Performance
Raritan, NJ 08869, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
<p>This is a cost-plus-fixed-fee definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency, to Janssen Vaccines & Prevention B.V. (JPC), a foreign-owned for-profit organization. The $196,408,488.00 contract does not have a set-aside designation and has an ultimate completion date of March 30, 2026. The contract was awarded on September 28, 2017.</p>
This is a cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services. The contract, with a ceiling value of $86,670,401.90, is for biomedical (advanced) products and services. The prime contractor is Janssen Vaccines & Prevention B.V., a foreign-owned for-profit organization. The contract does not have a set-aside designation and has an ultimate completion...
<p>This is a $233,343,418.86 definitive cost contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency, to Hoffmann-La Roche Inc. on September 15, 2016. The contract is for the "Combating Multi-Drug Resistance and Addressing Emerging Bacterial Threats: Discovery, Clinical Development" program and has an ultimate completion date of December 31, 2026. The contract was not set aside for any specific business type.</p>
This federal contract award, valued at $330,136,246.14, was granted by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the U.S. Department of Health and Human Services, to 4J Therapeutics Inc., a self-certified small disadvantaged business. The contract's objective is to demonstrate the versatility and efficacy of 4J Therapeutics' programmable antiviral technology platform by assembling a preclinical package for LNA14, performing a Phase 1a...
This is a $1,403,362,669.10 cost-plus-fixed-fee contract awarded by the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response to Emergent Product Development Gaithersburg Inc., a for-profit limited liability company manufacturing medical countermeasures and pharmaceuticals. The contract, which has a period of performance through September 29, 2026, is for the development of filovirus treatments. Emergent has received over $1.3...
The Department of Health and Human Services' Biomedical Advanced Research and Development Authority awarded a $269,952,453 firm fixed price definitive contract to Global Health Investment Corporation, a nonprofit organization. This contract establishes a public-private partnership through BARDA's other transaction authority to address gaps in pandemic preparedness and response. Specifically, the partnership will foster and accelerate medical countermeasure development using strategic venture...
This is a $38,199,745.00 definitive, cost-plus-fixed-fee contract awarded to Mapp Biopharmaceutical, Inc., a biotechnology company based in San Diego, California, by the Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR). The contract is for the development of medical countermeasures through planned clinical trials and outbreak preparedness, supporting ASPR's mission to prepare for and respond to public health emergencies. The...
This is a $1,649,690,592.00 Firm Fixed Price definitive contract awarded by the Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response to Bavarian Nordic A/S, a for-profit biotechnology company focused on developing cancer immunotherapies and infectious disease vaccines. The contract has no set-aside designation and a completion date of September 26, 2027.
Bavarian Nordic A/S has a history of supporting federal vaccine research and development...
This is a Cost Plus Fixed Fee contract awarded by the Department of Health and Human Services' National Institutes of Health (DHHS NIH) to Janssen Vaccines & Prevention B.V., a foreign-owned, for-profit organization, for the production of adenoviral vector vaccines. The contract has a potential value of $82,806,174.12 and a completion date of September 14, 2011. The contract is not set aside for any specific business type. The award is not associated with a larger vehicle. The contract is...
This is a $167,067,962 definitive cost-sharing contract awarded to Venatorx Pharmaceuticals Inc. by the Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR). The contract, which does not have a set-aside designation, supports the advanced research and development of new antibiotics to treat drug-resistant gram-negative bacteria, including public health pathogens. This work aligns with BARDA's mission to develop medical countermeasures...